| 3.64 0.11 (3.12%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.82 |
1-year : | 10.29 |
| Resists | First : | 6.69 |
Second : | 8.81 |
| Pivot price | 4.06  |
|||
| Supports | First : | 3.28 |
Second : | 2.72 |
| MAs | MA(5) : | 3.65 | MA(20) : | 4.44 |
| MA(100) : | 3.15 |
MA(250) : | 3.52 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 7.9 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 8.81 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ QLGN ] has closed above bottom band by 29.8%. Bollinger Bands are 31.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.98 - 6 | 6 - 6.02 |
| Low: | 3.47 - 3.49 | 3.49 - 3.5 |
| Close: | 3.61 - 3.64 | 3.64 - 3.66 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Fri, 24 Oct 2025
Qualigen Therapeutics Inc. (QLGN) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Fri, 24 Oct 2025
Qualigen Therapeutics Rebrands to Crypto Market - timothysykes.com
Fri, 24 Oct 2025
Qualigen Therapeutics (QLGN) Stock Surges on BitGo Partnership for $30M Crypto Allocation - parameter.io
Fri, 24 Oct 2025
Crypto Boom: Is Qualigen Shifting the Horizon? - StocksToTrade
Fri, 24 Oct 2025
Qualigen Therapeutics (QLGN) Stock: Jumps on BitGo Partnership to Diversify $30M Treasury Portfolio - CoinCentral
Fri, 24 Oct 2025
Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 187 (K) |
| Shares Short P.Month | 34 (K) |
| EPS | 6.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -171.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | 0.57 |
| PEG Ratio | 0 |
| Price to Book value | -1.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|